What are Sodium Channel Blockers (SD Inhibitors)
Sodium channel blockers (also called sodium channel inhibitors or SD inhibitors) are medications that block voltage-gated sodium channels, primarily used as antiarrhythmic drugs (Class I agents), anticonvulsants, and for neuropathic pain management.
Mechanism of Action
Sodium channel blockers work by inhibiting voltage-gated sodium channels, which are critical for action potential generation and propagation in excitable tissues (cardiac muscle, neurons, skeletal muscle). These agents prevent rapid sodium influx during cellular depolarization, thereby reducing cellular excitability 1.
Common Agents by Clinical Use
Antiarrhythmic Agents (Class I)
Class Ic agents (use-dependent sodium channel blockers):
- Flecainide - requires concurrent AV nodal blocking agent (β-blockers or non-dihydropyridine calcium channel blockers) to prevent 1:1 AV conduction during atrial flutter 2
- Propafenone - same precautions as flecainide 2
Important contraindications for Class Ic agents 2:
- LVEF < 40%
- Ischemic heart disease or history of MI
- Advanced AV block or significant conduction disorders
- Severe renal impairment (CrCl < 35 mL/min)
- Significant LV hypertrophy
Anticonvulsants/Antiepileptic Drugs
Second-generation agents 3:
- Lamotrigine
- Oxcarbazepine
- Topiramate
- Zonisamide
Third-generation agents 3:
- Lacosamide
- Eslicarbazepine
- Rufinamide
Neuropathic Pain Management
Sodium channel blockers for diabetic peripheral neuropathy (DPN) 4, 5, 6:
- Lamotrigine
- Lacosamide
- Carbamazepine
- Oxcarbazepine
- Valproic acid
Five medium-quality studies support their role in treating pain in DPN 4, 5, 6.
Other Sodium Channel Blockers
- Lidocaine - used intravenously for refractory VT/cardiac arrest; topically as 5% patch for localized neuropathic pain (limited to 12 hours per 24-hour period) 1, 6
- Mexiletine - oral agent for congenital long QT syndrome 1
- Quinidine - for Brugada syndrome 1
Critical Safety Considerations
Proarrhythmic Risk
Sodium channel blockers increase mortality in patients with ischemic heart disease 1. They should be avoided for chronic therapy in post-MI patients based on increased mortality observed in clinical trials 7.
Drug-Induced Arrhythmias
When sodium channel blocker toxicity occurs 7:
- Administer sodium bolus (sodium chloride or sodium bicarbonate) to reverse conduction slowing
- Consider β-blockers for frequent or cardioversion-resistant VT
- For atrial flutter with 1:1 AV conduction: add diltiazem, verapamil, or β-blocker
Tricyclic Antidepressants
TCAs (amitriptyline, maprotiline) have sodium channel blocking properties and can cause 7, 8:
- PR and QRS prolongation
- Brugada syndrome-like ECG patterns
- Increased cardiac arrest risk (OR 1.69)
- Do NOT use Class IA, IC, or III antiarrhythmics as they exacerbate cardiac toxicity 9
Monitoring Requirements
For Class Ic agents 2:
- Baseline ECG and repeat after initiation
- Monitor for QRS prolongation > 25% from baseline (increases proarrhythmia risk)
- Consider formal ischemia assessment before initiation in patients > 50 years or with atherosclerotic risk factors
- Annual assessment for CAD symptoms during long-term use
Important Distinction: NOT SGLT2 Inhibitors
Do not confuse sodium channel blockers with SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors like empagliflozin, dapagliflozin, canagliflozin), which are entirely different medications used for diabetes, heart failure, and chronic kidney disease 10, 11, 12, 13.